UNLIMITED FREE ACCESS TO THE WORLD'S BEST IDEAS

close
Already an Engineering360 user? Log in.

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

Customize Your Engineering360 Experience

close
Privacy Policy

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

EPA - 40 CFR PART 798

HEALTH EFFECTS TESTING GUIDELINES

active, Most Current
Organization: EPA
Publication Date: 1 July 2015
Status: active
Page Count: 85
scope:

Purpose. In the assessment and evaluation of the toxic characteristics of a chemical, the determination of subchronic dermal toxicity may be carried out after initial information on toxicity has been obtained by acute testing. The subchronic dermal study has been designed to permit the determination of the no-observed-effect level and toxic effects associated with continuous or repeated exposure to a test substance for a period of 90 days. The test is not capable of determining those effects that have a long latency period for development (e.g., carcinogenicity and life shortening). It provides information on health hazards likely to arise from repeated exposure by the dermal route over a limited period of time. It will provide information on target organs, the possibilities of accumulation, and can be of use in selecting dose levels for chronic studies and for establishing safety criteria for human exposure.

Document History

July 1, 2019
HEALTH EFFECTS TESTING GUIDELINES
A description is not available for this item.
40 CFR PART 798
July 1, 2015
HEALTH EFFECTS TESTING GUIDELINES
Purpose. In the assessment and evaluation of the toxic characteristics of a chemical, the determination of subchronic dermal toxicity may be carried out after initial information on toxicity has been...
July 1, 2014
HEALTH EFFECTS TESTING GUIDELINES
A description is not available for this item.

References

Advertisement